Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading REVB daily closes…
Loading price history…
Pipeline assets
GEM-AKI
Phase 2 · ActiveModality: Formulation of PHAD (TLR4 agonist)
Aliases Gemini
Target TLR4
Partnerships Vanderbilt University (licensed patent directed to methods of using PHAD for treating or preventing infections)
Indications
Acute kidney injury (AKI)(Phase 2)
Catalysts
— 2026
Status note Single Phase 2/3 adaptive design study agreed with FDA at end of 2025. During 2026 the company plans to build infrastructure (scientific advisory board, CRO engagement, blinded drug/placebo manufacture) to start the study as soon as feasible.
GEM-CKD
Preclinical · ActiveModality: Formulation of PHAD (TLR4 agonist)
Aliases Gemini
Target TLR4
Indications
Chronic kidney disease (CKD)(Preclinical)
Catalysts
— 2026
Status note Chronic (long-term) treatment for CKD. During 2026 the company intends to conduct preclinical toxicology studies to support a repeat-dose Phase 2 study.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.